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VITAMIN D TO REDUCE LIVER FIBROSIS IN NON-ALCOHOLIC FATTY 
LIVER DISEASE 
 
RYAN FOX 
ABSTRACT 
Background 
As the prevalence of metabolic risk factors in the American population has increased 
over time, so too has the diagnoses of non-alcoholic fatty liver disease (NAFLD).  Within 
this spectrum of disease lies the potential for silent progression towards cirrhosis, leaving 
the patient with few options for treatment.  Currently, the standard of care remains 
counseling on diet and exercise with the goal of reversing disease progression by 
addressing the underlying risk factors.   
Literature Review 
Recent studies have shown that a correlation exists between low levels of serum 25-
hydroxyvitamin D and hepatic injury from NAFLD.  This has become an active area of 
research, due in part to the anti-inflammatory and immunoregulatory properties of 
vitamin D.  The prospect of a simple and cost effective intervention that can exert its 
effects on the mechanisms behind the development of NAFLD is interesting and warrants 
further research. 
Proposed Project 
This proposal is for a double-blind, randomized, experimental study of vitamin D3 
(cholecalciferol) versus placebo in a patient population of those with both clinically 
  vi 
proven NAFLD and concomitant vitamin D deficiency.  Liver fibrosis will be measured 
and staged with the use of FibroScan elastography.  The statistical analysis thereafter will 
determine if a clinically significant reduction in hepatic fibrosis exists, compared with the 
results of the placebo group. 
Conclusions/Significance 
Should vitamin D prove to be an effective treatment option in reversing the progression 
of NAFLD, clinicians would be equipped with a simple and safe tool to augment their 
management of the patient.  For those that experience barriers (i.e. lower socioeconomic 
status, other comorbidities, etc.) preventing them from improving diet and exercise, 
vitamin D would serve as an alternative therapy to aid in reducing their disease burden.  
Easier methods to treat their disease now projects improved quality of life years later. 
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INTRODUCTION 
Background 
Non-alcoholic fatty liver disease (NAFLD) is a term used to refer to a spectrum of liver 
disease that ranges from the relatively benign simple hepatic steatosis to the far more 
severe and life threatening cirrhosis.  As the name suggests, this condition is not a result 
of alcohol consumption, but rather heavily associated with many of the same risk factors 
that comprise metabolic syndrome such as obesity, dyslipidemia, and elevated blood 
glucose.  In fact, the literature commonly refers to NAFLD as the hepatic manifestation 
of metabolic syndrome.  NAFLD is a major public health concern as it is the current 
leading cause of chronic liver disease in both adult and children in Western populations1.  
At its core, NAFLD is the accumulation of excess triglycerides within the hepatocyte.  
This occurs through various mechanisms such as lipolysis of dietary sources, adipose 
tissue, and lipogenesis within the body2.   
Recently, concomitant Vitamin D deficiency (VDD) in the setting of NAFLD has 
received more attention, with the association between the two being firmly established in 
various studies3-5.  Recent studies have elucidated the expanded role Vitamin D plays in 
the human body outside of bone and calcium homeostasis, including exerting effects in 
inflammatory and immune pathways6.  Such pathways have been shown to be involved in 
the pathogenesis of NAFLD and are currently a focus of research as a potential 
therapeutic target for the use of vitamin D supplementation.   
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Statement of the Problem 
The existence of VDD in patients with NAFLD compounds their problems, predisposing 
them not only to issues surrounding bone and calcium homeostasis, but also exacerbated 
hepatic steatosis, necroinflammation, and fibrosis, all of which expedite the disease 
course towards cirrhosis2.  While the association between VDD and NAFLD has been 
firmly established, the number of studies that have aimed to assess its therapeutic 
potential in humans is quite limited.  According to the US Department of Health and 
Human Services, currently no pharmacologic treatment exists for NAFLD and the 
standard of care is to counsel the patient on leading a healthy lifestyle, including changes 
in diet and exercise7.  Should the liver disease progress to the point of cirrhosis the only 
treatment option available is transplantation.  Beyond the risks associated with transplant 
surgery, it is estimated that the list of adults awaiting a healthy liver has almost tripled 
since 2004, thus demand is a significant issue as well8.  This sets the stage for research 
into alternative methods such as Vitamin D supplementation that could be used to delay 
or even reverse NAFLD progression. 
 
Hypothesis 
Supplementation with Vitamin D3 (25(OH)D3) in patients with Non-Alcoholic Fatty 
Liver Disease and concomitant Vitamin D Deficiency will provide a significant reduction 
in hepatic fibrosis. 
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Objectives and specific aims 
The aim of this study is to evaluate the efficacy of vitamin D supplementation as a 
treatment option that would aid in the reduction of hepatic fibrosis and steatosis in 
patients with NAFLD.  Rigorous lifestyle changes involving diet and exercise are often a 
challenge for patients to maintain, and while this would not fully replace such 
interventions, it would provide both the healthcare provider and the patient another tool 
to aid in the fight against their disease progression.  Vitamin D is cost-effective, simple, 
and safe, making it an attractive option should it prove efficacious. 
Specific aims: 
1. To quantify any potential reduction of hepatic fibrosis as a result of Vitamin D 
supplementation 
2. To quantify any potential reduction of hepatic steatosis as a result of Vitamin D 
supplementation 
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REVIEW OF THE LITERATURE 
Overview 
An overwhelming proportion of today’s society has grown increasingly comfortable with 
a sedentary lifestyle; the conveniences that new technology, economically friendly fast 
food, and the ever-growing sources of entertainment are difficult to deny.  An unfortunate 
result of all this is seen in the large prevalence of metabolic syndrome.  Metabolic 
syndrome is characterized by central obesity, insulin resistance, elevated fasting blood 
glucose, hypertension, dyslipidemia, and poor cholesterol9.  Many of these features are 
also seen in non-alcoholic fatty liver disease (NAFLD) and thus it is often referred to as 
the hepatic manifestation of metabolic syndrome.  It is reported that worldwide there is 
approximately a 20% prevalence of NAFLD in the general population; however, Western 
countries are at an increased risk due to the staggering 34% of United States citizens that 
are estimated to exhibit metabolic syndrome9.  As a consequence, reports estimate that 
the incidence of NAFLD in the US ranges from 10% to 30%10.   
 The term NAFLD does not refer to one particular disease itself, but rather a 
spectrum of diseases that ranges from simple hepatic steatosis, to non-alcoholic 
steatohepatitis (NASH), to the most severe outcome known as cirrhosis.  In simple 
steatosis, liver fat is present but there is no hepatocellular injury, while in NASH there is 
both liver fat and hepatocellular injury present and it may or may not include fibrosis11.  
Due to the close relationship between metabolic syndrome and NAFLD, many of the risk 
factors overlap.  The most prevalent instigators are obesity, type 2 diabetes mellitus, and 
hypertriglyceridemia resulting in 60-95%, 28-55%, and 27-92% of NAFLD cases 
 5 
respectively12.  Fat distribution is often a greater predictor of morbidity than is body mass 
index (BMI), and NAFLD is no exception, with visceral fat being associated with a 
greater degree of inflammation and fibrosis13.  That being said, 30% to 37% of obese 
individuals exhibit simple hepatic steatosis and exerts an additive effect when combined 
with other predisposing factors to NAFLD14.  Type 2 diabetes is not only often seen in 
conjunction with NAFLD, but is also thought to increase the progression of liver 
disease14.  In fact, a recent study showed that of 3,861 patients with Type 2 diabetes, 
1,751 of them also had NAFLD15.   
 In addition to metabolic risk factors, age, gender, and ethnicity have also been 
reported to increase the likelihood of developing NAFLD.  Studies that divided the 
population by age ranges showed that with increasing age there is a greater prevalence of 
NAFLD and fibrosis, though this can partly be attributed to the increased comorbidities 
of the elderly that serve as risk factors, as well as the longer duration of disease14.  
Previously thought to be more common in women, NAFLD is found to be more common 
in men with one study showing a 31% and 16% prevalence on routine medical check-up 
in men and women respectively16.  In terms of ethnicity, Hispanics exhibit the highest 
prevalence, followed by Caucasians, and with lowest prevalence in African Americans.  
The research behind these relationships is ongoing, but one study noted that the differing 
rates between Hispanic and African Americans could potentially be attributed to fructose 
malabsorption in the latter, providing a protective effect against liver steatosis17.   
 Understanding of the pathogenesis of NAFLD has undergone multiple evolutions 
throughout the past and is still a subject of debate.  This is largely due to the many 
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contributing factors that play a role in the disease progression, as opposed to one isolated 
mechanism.  Originally the accepted idea was a “two hit” hypothesis in which the first hit 
was when the liver parenchyma became sensitized by hepatic steatosis.  This then 
enabled a metabolic stressor to act as the second hit which triggered inflammation, 
steatonecrosis, and fibrosis that characterize the disease18.  Currently it is believed that 
this theory is an oversimplification and as previously mentioned, many various 
mechanisms all play a role in what is now termed the “multiple-hit” hypothesis.   
While many contributing mechanisms play a part in the complex pathophysiology 
of NAFLD, the development of insulin resistance and hepatic inflammation are the most 
pertinent for the scope of this paper in regards to the role Vitamin D plays.  The core 
issue in NAFLD is hepatic steatosis which is believed to occur as a result of free fatty 
acids (FFAs) liberated via lipolysis of adipocytes, as well as lipids ingested in the diet, 
lipogenesis within the body, and lipid disposal impairment4.  As a consequence of this 
excess buildup of FFAs, defects arise in insulin signaling as well as in glucose 
metabolism within cells.  This in turn leads to elevated blood glucose levels which elicits 
an increase in lipogenesis via an increase in activation of both sterol regulatory element 
binding proteins (SREBPs) and carbohydrate response element binding proteins 
(CHREBPs)4.  As this vicious circle continues, the degree of both hepatic and adipocyte 
insulin resistance as well as free fatty acid accumulation becomes more severe and thus 
propels the progression of NAFLD.   
One study found that subjects with NAFLD compounded the excess FFAs with a 
decreased ability to inhibit their oxidation, thus increasing their susceptibility to further 
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hepatic steatosis19.  Utzschnider and Kahn, 2006 summed up this complex physiology 
concisely by stating that “diminished insulin responsiveness at the level of the adipocyte 
may contribute to hepatic steatosis by excess FFA flux to the liver”19.  It is worth 
mentioning that this mechanism of insulin resistance occurs as one aspect of broader 
factors such as dietary habits, genetic, and environmental factors.   
For the individuals in which hepatic steatosis progresses towards NASH, chronic 
inflammation, due in part to insulin resistance, is the primary driving force behind it.  
Fortunately this occurs in only 10% to 20% of those with fatty liver, but the dire 
consequences that become apparent as the inflammation progresses warrants a thorough 
understanding of what causes it.  The reason behind why some patients’ steatosis 
progresses and others do not is not known, and it is worth mentioning that inflammation 
does not always occur after liver fat deposition.   
Adipose tissue has come to be regarded as a significant source of metabolic and 
immune related activity in the body, producing various cytokines that act on other organs.  
One such example that is thought to be highly involved in NAFLD is adiponectin.  This 
adipocytokine plays a protective role against inflammation and is found to be reduced in 
obese individuals and thus in a large portion of those with NAFLD20.  The deletion of 
Sirtuin 1, one of the two receptors in the liver which it acts through, has been shown to 
lead to both hepatic steatosis and inflammation21.  A study done with obese mice in 
which the isoform for adiponectin was overexpressed showed a reversal of the diabetic 
phenotype and normalization of blood glucose and insulin levels, leading to a reduction 
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in both insulin resistance and liver fat20.  In addition to adiponectin, leptin, resistin, and 
TNF-α have also been implicated in NAFLD development. 
Vitamin D is a fat soluble secosteroid hormone that is well known for its 
involvement in skeletal and calcium homeostasis.  Though humans can derive it from 
dietary sources such as oily fish (tuna, salmon, mackerel) or egg yolks, there exist few 
foods that naturally contain it.  To combat this, many foods in the US are fortified with 
Vitamin D to supplement the American diet.  For example, in the 1930s rickets was a 
major public health concern so in response, a milk fortification program was established 
and is still in place today22.  Barring supplements, humans get the majority of their 
Vitamin D through sunlight exposure, though various factors impact to what degree this 
occurs such as time of day, season, and melanin content in the skin.   
Recently, new light has been shed upon the role Vitamin D plays in the human 
body, particularly concerning the relationship between its serum levels and diabetes and 
cardiovascular disease.  Due to the close relationship NAFLD has with such conditions, 
researchers were prompted to investigate if Vitamin D levels had any contribution in its 
pathophysiology.  Inflammation and oxidative stress serve as the common ground 
between Vitamin D deficiency (VDD) and NAFLD.   
The liver is one of the primary sites for vitamin D metabolism from both the skin 
and diet, responsible for the hydroxylation of its inactive form into 25-hydroxyvitamin D 
[25(OH)D] via the enzyme 25-hydroxylase.  From the liver, 25(OH)D travels to the 
kidneys where 1α-hydroxylase converts it to the biologically active form 1α,25-
dihydroxyvitamin D [1,25(OH)2D]23.  Vitamin D receptors (VDRs) are expressed 
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abundantly throughout the body and they are the means by which Vitamin D exerts its 
biological effects.   Examples of where VDR can be found include immune cells, 
adipocytes, non-parenchymal hepatocytes, β cells of the pancreas, and skin tissue6.  
While the exact mechanisms are not yet fully understood, it is thought that through the 
VDR constitutively expressed on macrophages and lipopolysaccharide-stimulated 
macrophages that Vitamin D is able to function as an anti-inflammatory agent24.  
1,25(OH)2D3 upregulates the inhibitor of nuclear factor NF-κB, a key player in the pro-
inflammatory signaling pathway, through increasing the stability of mRNA and reducing 
phosphorylation of NF-κB24. 
Vitamin D deficiency (VDD) has long been thought to almost exclusively affect 
the elderly and hospitalized patients, but its prevalence outside such demographics has 
slowly been increasing over the past years.  Regarding NAFLD, researchers have shown 
that there exists an association with VDD.  One study found that of 6,800 patients from 
the National Health and Nutrition Examination Survey (NHANES III) database, 308 
exhibited an elevation in alanine aminotransferase (ALT) that could not be explained.  
When the Vitamin D levels of these patients were compared with those of the 979 
matched controls, it was found that the NHANES III patients had lower levels, despite 
metabolic syndrome, insulin resistance (IR), and triglycerides being controlled for25.  
Another study further illustrated this when they found that the association between VDD 
and NAFLD maintained despite age, gender, IR, and triglycerides26.  Finally, in a study 
done by Targher et al., NAFLD patients were again shown to have markedly lower levels 
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of serum 25(OH)D, but in addition they evaluated liver histopathologic features and 
found there to be a linear relationship27.   
The clinical course varies depending on the stage of NAFLD the patient has and is 
broadly divided into two categories: non-NASH and NASH.  In simple hepatic steatosis 
(or non-NASH) the disease progression, if any, is normally very slow and mostly 
benign11.  Conversely, in NASH there can be histological progression that may ultimately 
lead to cirrhosis14.  5% to 20% of patients with simple steatosis will progress to NASH, 
10% to 20% of those will go on to develop more severe fibrosis, and <5% of those end up 
with cirrhosis28.  In terms of mortality, a community based report of NAFLD patients in 
Minnesota looked at a mean follow-up of 7.6 years and observed 13% mortality, with 
higher mortality rates associated with NASH29.  For patients that have progressed to the 
point of advanced fibrosis and cirrhosis, development of hepatocellular carcinoma (HCC) 
becomes a risk11.  Fortunately, disease progression in NAFLD is reversible.   
 Treatment for NAFLD requires addressing not only the liver disease itself, but the 
other metabolic comorbidities that are often present as well, such as obesity, Type 2 
Diabetes Mellitus, and hypertriglyceridemia.  Fortunately in simple hepatic steatosis there 
is little, if any, liver disease present so the primary focus for treatment becomes lifestyle 
interventions.  Currently, no pharmaceutical therapy exists that is used to specifically 
treat NAFLD and the most effective treatment involves adhering to strict lifestyle 
changes as well as maintained weight loss.  The recommendations set forth by the 
American Gastroenterological Association state that a reduction in hepatic steatosis 
generally follows weight loss of at least 3% to 5% of total body weight; however, a 
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weight loss of up to 10% of body weight may be necessary in order to improve 
necroinflammation11.  The effect of solely exercise in patients with NAFLD is not as well 
established but it is thought that an improvement can be seen in hepatic steatosis, though 
any effect on liver histology is unknown.  
 In addition to lifestyle interventions, various other therapies are being explored 
that revolve around treating the comorbidities.  Vitamin E’s anti-oxidant properties allow 
it to work against oxidative stress that contributes towards hepatocellular injury in 
patients with NASH2.  However, high-dosage interventions have been linked to both 
increased mortality as well as hemorrhagic stroke and prostate cancer, though this is still 
a topic of debate30.  Another treatment option for patients with biopsy-proven NASH is 
Pioglitazone; however, the long term safety of thiazolidinediones is still an active area of 
research.  For this reason, Pioglitazone’s use is heavily restricted in the United States and 
is no longer available in Europe11.  With a large proportion of NAFLD patients being 
obese, bariatric surgery has become a viable option to help reverse their disease 
progression.  Various studies have shown a decrease in hepatic steatosis as well as 
fibrosis in patients who underwent bariatric surgery28.  One meta-analysis showed an 
improvement or complete resolution of steatosis, steatohepatitis, and fibrosis following 
bariatric surgery, but due to a lack of randomized clinical trials a definitive 
recommendation cannot be made31.   
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Existing research 
The concept that Vitamin D could have a potential therapeutic impact on the disease 
progression of NAFLD is fairly novel, but several studies have been done that have 
sought to explore the possibility.  Evidence has been published involving both human and 
animal subjects and while there are some conflicting results, it remains to be seen if 
Vitamin D can ameliorate NAFLD over an extended time interval.  The Farnesoid X 
Receptor Ligand Obeticholic Acid in NASH Treatment (FLINT) trial published in 2014 
established 72 weeks as the time period to monitor the liver for changes in fibrosis32. 
One of the hallmark studies that helped lay the foundation for future research into 
this topic was a rat study performed by Nakano et al. in 201133.  The stimulus that 
prompted research into this area was the lack of both quality and availability of liver 
transplants, in addition to their increasing need as NASH grew in prevalence.  
Phototherapy as well as Vitamin D3 supplementation was used as a means of increasing 
serum Vitamin D3 levels in an attempt to slow down disease progression in NASH.  
Following a 12 week diet that resulted in 36 rats with livers that exhibited steatosis, 
NASH, and fibrosis, they were divided into four groups: 6 or 12 weeks of phototherapy 
and 6 or 12 weeks as control.  Phototherapy was likely chosen as the means for 
supplementation as that is the way in which the vast majority of the world population 
obtains Vitamin D and VDD is very much a global health issue.  However, in addition to 
sunlight exposure the rats were also administered oral 1α-hydroxy-cholecalciferol 
(1α(OH)D3) three times per week for six weeks in order to better examine effects of 
Vitamin D.   
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 The significant finding that came out of this study was that phototherapy proved 
to be efficacious in delaying the progress of NASH, but it did not reduce hepatic 
steatosis.  This showed that the anti-inflammatory and anti-fibrotic activity possessed by 
Vitamin D was able to ameliorate disease progression in NASH.  They also referenced 
other beneficial effects of Vitamin D that may have contributed to this finding, including 
improvement in insulin sensitivity and its anti-apoptotic effect on hepatocytes, other key 
mechanisms involved in NAFLD pathophysiology.   
 The association of VDD with fibrosis that develops in NAFLD served as a 
foundation for a study that hypothesized vitamin D supplementation in addition to 
docosahexanoic acid (DHA) would be efficacious in treating a pediatric cohort.  The 
rationale cited in the study discusses the role VDD in inflammation and oxidative stress, 
consequently predisposing the individual to hepatic fibrosis.  DHA, a type of omega-3 
fatty acid has been shown to aid in the reduction of hepatic steatosis in NAFLD 
patients34.  
 The study design was a randomized control trial with two arms, one administered 
800 IU of vitamin D and 500 mg of DHA and the other a placebo.  Intervention took 
place over the course of 24 weeks.  The primary outcome for the authors’ hypothesis was 
improvement in liver histology, determined by comparing a baseline biopsy for each of 
the 20 subjects in the VDD/DHA group to one at the conclusion of the study.  Overall, 
the NAFLD Activity Score (NAS), a summation of liver histology marker scores, 
improved from 5.40 to 1.92.  Significant improvements were observed in steatosis (2.25 
to 1), ballooning (1.6 to 0.46), lobular inflammation (1.5 to 0.88), and portal 
 14 
inflammation (1.6 to 1.0)34.   However, despite the modest improvement in fibrosis (2.0 
to 1.5), it failed to be statistically significant.  Consistent with the research the study was 
founded upon, lower levels of 25-hydroxyvitamin D were associated with patients 
exhibiting greater levels of steatosis and fibrosis34.  From their data, the researchers were 
able to determine that vitamin D aided in the reduction of hepatic stellate cell and 
myofibroblast activation, both of which contribute toward development of liver fibrosis34.   
 Regarding lab values such as triglyceride and ALT related to metabolic syndrome 
that are so commonly associated with NAFLD, the authors came to an interesting 
conclusion.  The treatment group exhibited a decline in these values, as well as insulin 
resistance, but the data was compared to a past trial they performed.  Said trial examined 
the role of DHA in NAFLD when compared to vitamin D in a pediatric population in 
regards to their effect on the metabolic profile.  It was revealed that no significant 
difference existed between the vitamin D and DHA group, thus in this trial, the 
improvement of triglycerides, ALT, and insulin resistance is attributed to only DHA with 
likely no contribution from vitamin D34.   
 This study helps promote vitamin D as a therapeutic option to treat NAFLD but 
certain limitations exist that necessitate further research.  The pediatric focus of the study 
helps establish a greater font of knowledge for the growing population of children with 
NAFLD, but unfortunately makes it difficult to translate the authors’ findings to an adult 
population.  For ethical reasons it is understandable that biopsies only were performed on 
the treatment group, though having samples from the control group would help better 
characterize the true value of vitamin D and DHA in NAFLD.  Lastly, there were no 
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patients included in the study that had cirrhosis or bridging fibrosis, so the results can 
only be applied to those with mild to moderate NAFLD. 
 A recent cross-sectional analysis performed in 2016 was published in the 
American Journal of Gastroenterology that approached the relationship between Vitamin 
D and NAFLD from a slightly different angle.  Through their research they explored if 
the Vitamin D levels in the subjects correlated with NAFLD severity, using degree of 
hepatic steatosis, lobular inflammation, ballooning hepatocytes, and stage of fibrosis as 
their primary outcomes.  244 adults with biopsy-proven NAFLD comprised one cohort 
while 39 controls made up the other, a respectable sample size for the former that lends 
credibility to the study.  Consistent with previous studies, vitamin D levels were found to 
be significantly different based on the individual’s weight, with lower serum levels 
correlated with increasing BMI35.  However, the histological analysis failed to find any 
significant relationship between vitamin D levels and the primary outcomes35.  
Interestingly, vitamin D levels actually increased with stage of fibrosis, shown in Table 1. 
Table 1: Fibrosis and VitD 
Fibrosis Stage 25-OH Vitamin D level 
0 24.4±4.4 
1 26.5±8.9 
2 29.1±12.5 
3 30.7±4.1 
4 20.2±20.2 
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While there was found to be a lower vitamin D level in patients with stage IV fibrosis, the 
number of patients with that level of disease severity was too small to be statistically 
significant35.   
  
One strength of this study was the attention paid to the control cohort, as the 
researchers ensured that the subjects included were similar to the NAFLD group in as 
many ways possible.  This includes comparable gender, age, and BMI, as well as 
presence of vitamin D deficiency and risk factors for metabolic syndrome35.  Combined 
with the large and diverse sample size, the results can be well generalized.  Regarding 
weaknesses, vitamin D supplementation by subjects prior to the study was difficult to 
quantify due to the retrospective nature of patient selection.   
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METHODS 
Study design 
The proposed study will be a double-blind, placebo-controlled randomized experimental 
study comparing two treatment arms, vitamin D supplementation and a placebo. 
Study population and sampling 
The study population for this trial will consist of consenting patients age between 18-70 
with a formal diagnosis of NAFLD as well as vitamin D deficiency.  Initial NAFLD 
diagnosis will be defined according to the histological parameters established by the 
NASH Clinical Criteria Network, which includes hepatic steatosis >5%, presence of 
necroinflammation, ballooned hepatocytes, or hepatic fibrosis36.  Diagnosis for Vitamin 
D deficiency will be defined as any serum value <30 ng/ml.  Exclusion criteria will 
include consumption of alcohol that exceeds 14 or more servings per week for men or 7 
or more servings per week for women, serological evidence of other forms of hepatic 
disease (i.e. Wilson’s disease, hereditary hemochromatosis, chronic viral hepatitis, α1-
antitrypsin deficiency), or any histological evidence of potential co-existing hepatic 
disease.  In addition, patients who have reported consumption of vitamin D supplements 
or medications with hepatotoxic side effects within the last 6 months will also be 
excluded.  There will be no exclusions for patients based on gender, ethnicity, or 
metabolic risk factors.  Sample size appropriate for this study will be approximately 115 
patients in each group for a total of 230 participants, using 80% power and an alpha of 
0.05 to detect a decrease of 1 stage of fibrosis on FibroScan37. 
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Treatment 
The intervention in this study will consist of treatment with either vitamin D 
supplementation or a placebo.  Subjects in the Vitamin D supplementation treatment arm 
will be administered 10,000 IU of vitamin D3 (cholecalciferol) daily, while subjects in 
the placebo arm will be administered a pill that is similar in size, color, shape, and 
package.  These interventions will take place over the course of 16 months, as per the 
standard set forth in the FLINT trial for accurately assessing change in hepatic fibrosis32.  
Subjects will be both randomized and blinded into which intervention they receive and 
they will receive instruction as to how to take the pill each day.  Researchers will be 
blinded to which medication they are administering and will assess compliance based on 
number of pills remaining every 2 months.  Researchers will also inquire about any side 
effects at that time.   
Study variables and measures 
The independent variable of this study will be the administered medication, whether it be 
vitamin D or placebo.  The dependent variable that will be analyzed is the stage of 
fibrosis determined by FibroScan.  FibroScan is an imaging modality used to perform 
ultrasound-based elastography, an FDA approved non-invasive technique that serves as a 
tool to assess for hepatic fibrosis.  Stage of fibrosis will be gauged using the assigned 
values of F≤1=mild, F≥2=moderate, F≥3=severe, and F4=cirrhosis38.  Scans will be 
performed at intervals throughout the study: once prior to the start of the study to 
establish a baseline for each patient, followed by one every 4 months until the conclusion 
of study.  Comparisons will be made between the patient’s baseline score and the 
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subsequent scans.  The primary end point of the study will be to determine if 
supplementation with vitamin D helped to ameliorate the degree of fibrosis from the 
baseline after a 16 month intervention period.    
Recruitment 
Subjects will be referred to this study by the liver specialists at Boston Medical Center 
who deem them to be within the outlined parameters for entry.  This includes a formal 
diagnosis (i.e. liver biopsy, elastography, etc.) of NAFLD that exhibits mild to moderate 
fibrosis, as well as concomitant vitamin deficiency.  Following referral, potential subjects 
will then be assessed by clinical members of the study to confirm that they fall within the 
designated criteria. 
Data collection 
Prior to the start of the study, subjects who agree to participate will undergo an initial 
FibroScan test and blood draw in order to determine baseline hepatic fibrosis and serum 
25-hydroxyvitamin D level respectively.  Following the initial tests, subjects admitted to 
the study will be randomized into either the vitamin D or placebo treatment arms and 
begin receiving their assigned medication protocol.  Subjects will be instructed to take 
their medication once daily in the morning.  This will last for a 16 month period, in which 
repeat FibroScans will be obtained at 4 months intervals throughout the study.  In 
addition, subjects will be asked about any side effects or worsening symptoms at each 
interval to ensure there is no evidence of severe liver disease progression, hypercalcemia, 
or vitamin D toxicity.   
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Data analysis 
To determine if and to what extent there was a decrease in the patient’s stage of fibrosis 
following the treatment regimen, their baseline FibroScan will be compared to 
subsequent scans performed at 4 month intervals.  To adjust for potential confounders, 
data will be stratified into categories based on the subject’s age, gender, BMI, skin tone, 
and grade of hepatic fibrosis.  Both standard deviation and mean will be calculated for 
each treatment group.  A Chi-Square test will be used to compare the vitamin D 
supplementation group with the placebo group.  To assess for variance, ANOVA will be 
used. 
Timeline and resources 
The timeline for this study will be a 16 month interventional period.  Prior to beginning 
the study, time will need to be allowed for recruiting potential subjects, researchers, 
planning and approval by the IRB.  Considering these requirements, it is reasonable to 
approximate the start of this study to be in April of 2017.  Accounting for the number of 
subjects involved and the relatively limited access to FibroScan machines, start date for 
subjects will likely need to be staggered.  Conclusion of the study will consequently be 
August of 2018.  FibroScans will be performed at 4 month intervals through the 
conclusion of the study, which necessitates access to multiple FibroScan machines at 
such times in order to efficiently handle the patient load. 
 Research staff will consist of one primary investigator whose job it will be to lead 
and coordinate the study, while 4-5 clinicians will be responsible for oversight of the 
patients in the time leading up to and throughout the 16 month period.  The latter will 
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also be in charge of assessing the referrals from Boston Medical Center providers for 
potential admittance to the study.  Representatives from FibroScan will be requested to be 
made available for any teaching necessary for the clinicians to feel comfortable with 
operating the machine if they are not already. 
Institutional Review Board 
The proposed study will require use of human subjects, consequently an application to 
the Institutional Review Board of Boston University Medical Center will be submitted.  
Upon acquisition of approval by the IRB, patients will then be recruited for the study.  
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CONCLUSION 
Discussion 
The potential for Vitamin D, a simple, affordable, easy to manage medication to aid in 
reducing fibrosis in those affected by NAFLD is certainly an exciting prospect.  While 
this study will strive to fully elucidate any therapeutic benefit it may have, it does not 
come without its own weaknesses.  One of Boston Medical Center’s primary roles in the 
community is to serve as a “safety net” hospital, meaning that a vast majority of the 
patient population is of the lower socioeconomic demographic, insured by government 
programs such as MassHealth or Medicaid.  Furthermore, such a population 
unfortunately does not always have access to healthcare and medications that others may 
take for granted.  This culminates in a cohort that may not accurately reflect the 
exceedingly large population of individuals in the United States that have a diagnosis of 
NAFLD.  However, what said population lacks in generalizability related to 
socioeconomic status, it gains in racial background.  Boston Medical Center is in a 
unique position to have the privilege to provide care for a wide range of ethnicities, and 
consequently, outcomes of this study can be better generalized to those populations.   
 A weakness of this study can also be found in the technique used to assess stage 
of hepatic fibrosis.  Neither patients nor the IRB would find multiple liver biopsies, the 
current gold standard for evaluating fibrosis, to be an acceptable method of assessment 
due to the myriad risks as well as the pain that accompany it.  Thus, a non-invasive 
modality such as FibroScan is used alternatively.  While ultrasound is a quick, easy, and 
 23 
cost-effective method, it is limited by factors such as morbid obesity and hepatic 
inflammation39.   
Summary 
NAFLD is a highly prevalent disease in the United States and around the globe that 
predisposes affected individuals to potentially severe health consequences.  As NAFLD 
refers to a spectrum of disease burden that spans from benign hepatic steatosis to 
cirrhosis requiring liver transplantation, early intervention becomes paramount.  There 
remains to be seen a treatment option targeted directly at reversing the disease process 
beyond the current standard of care: diet and exercise.  Several studies performed in 
recent years have evolved from merely establishing a correlation between low serum 25-
hydroxyvitamin D and NAFLD, to evaluating the efficacy of its anti-inflammatory 
properties when elevated in animals.  
 Much debate still exists over the relationship between decreased serum vitamin D 
and NAFLD severity.  Should the hypothesis prove to be accurate, this study would add 
to the evidence supporting the use of vitamin D as a therapeutic option to reverse disease 
progression in patients with NAFLD.  This study would also provide an opportunity to 
learn more about the efficacy of FibroScan in regards to the assessment of disease 
progression specifically in NAFLD.  Currently, it is gaining traction in the United States 
since earning FDA approval.  Should it prove as a reliable and accurate imaging 
modality, its use may grow around the country, offering a fast and inexpensive test that 
can better characterize the state of a patient’s liver.   
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Clinical and/or public health significance 
The current state of healthcare in the United States has the potential to render treatment 
relatively inaccessible to a large number of people, often due to costly insurance 
premiums or medications.  Vitamin D is a safe, affordable, and easy to use supplement 
that, if proven to aid in reversing hepatic fibrosis in patients with NAFLD, could be an 
excellent tool in the belt of healthcare providers responsible for their treatment.  
Sedentary lifestyle and unhealthy food options remain highly prevalent in the US, and as 
consequence a vast number of new NAFLD diagnoses is maintained each year.  The 
patient may not notice the benefits of reduced fibrosis immediately, but the reversal of 
disease progression would spare them potentially severe health complications in later 
years.  The goal of this study is not to establish vitamin D as the sole treatment for 
NAFLD, but rather as a therapy aimed at augmenting the progress achieved through 
lifestyle and dietary changes.   
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